Diaverum Brand Guidelines: Gambro’s 1991 Clinic Arm, Now Part of Abu Dhabi’s M42

The clinic arm of a Lund dialysis maker.

Diaverum’s roots are in Gambro, the Swedish dialysis-equipment maker founded in Lund in 1964 by the industrialist Holger Crafoord, who, English Wikipedia says, set out to develop and market the artificial kidney devised by the Lund professor Nils Alwall. The Gambro name is a contraction of the original Swedish company name, Gamla Brogatans Sjukvårdsaffär Aktiebolag, roughly “the Old Bridge Street Medical Supplies Company.” Mass production began in 1967 with a dialyzer called “Ad-modum-Alwall,” and Gambro was listed on the Stockholm stock exchange in 1983.

Making equipment and running clinics are different businesses, and for a time Gambro did both. According to English Wikipedia, Gambro opened its first dialysis clinic in Lund in 1991, and the clinic side grew under the name Gambro Healthcare, managing about 150 clinics around the world by 2005. Diaverum’s own press releases give its founding as 1991 “in Malmö, Sweden,” so the company and the encyclopedia place that first year in two neighbouring cities of Skåne; we give both.

The split came in stages. In 2006 Gambro itself was bought out of the stock market by Indap, a company owned jointly by the Swedish investors EQT and Investor AB, Swedish Wikipedia says. In 2007 Gambro Healthcare was divested from Gambro and taken over by the private-equity firm Bridgepoint together with its management, and the name Diaverum was adopted in 2008, English Wikipedia says. The equipment side went its own way: Baxter International completed its purchase of Gambro in September 2013, and Vantive, the kidney-care company that separated from Baxter in 2025, lists that purchase in its own history. Diaverum was left as a clinic operator, with no machine maker as its parent.

Clinics, not machines.

Diaverum runs dialysis clinics. Its press releases describe a range of care that runs from preventive care and haemodialysis to peritoneal dialysis, home care, the coordination of patients’ other conditions and holiday dialysis, for patients who need treatment away from home. The company describes a “standardised care delivery model” with a digital and AI infrastructure behind it, and calls itself “the largest independent renal service provider in Europe.”

The figures it publishes have climbed steadily. In January 2025 Diaverum gave 13,500 healthcare professionals, more than 42,000 patients and 450 clinics in 24 countries. By April 2026 its company description read 14,200 professionals, around 45,000 patients and more than 460 clinics in 25 countries, and by September 2026 the count was 26 countries. Those are the company’s own figures, as of the dates given. When the sale to M42 was announced in April 2023, the Bahrain newspaper Gulf Daily News reported 440 clinics in 23 countries and more than 13,000 employees, and called Diaverum the world’s third-largest provider of dialysis services; English Wikipedia also ranks it third among clinic operators, after Fresenius Medical Care and DaVita.

Growth has come through public contracts, acquisitions and new countries. In Britain, English Wikipedia says, Diaverum has won several contracts since the Health and Social Care Act 2012 came into force in 2013, including, in 2020, a seven-year contract to run haemodialysis and outpatient services covering East Lancashire, North Lancashire and South Cumbria. In January 2025 the company announced plans to open in Abu Dhabi and Al-Ain in the United Arab Emirates. In April 2026 it said an acquisition in São Paulo state brought it to 18 clinics and three vascular access centres in Brazil. In September 2026 it opened its first clinic in Bishkek, Kyrgyzstan, in cooperation with the Kyrgyz government, offering state-funded dialysis to eligible patients.

Design and documentation.

Dialysis and kidney-care companies sell to two audiences at once. One is clinical: nephrologists, nurses, technicians and hospital buyers who choose machines, dialyzers and solutions. The other is the patient, who may spend several sessions a week in a treatment chair or carry out dialysis at home. Their imagery tends to answer both: a calm patient in a reclining chair beside a machine, a nurse in a bright, orderly clinic, and close-ups of dialyzers, tubing and the screens of haemodialysis machines.

Home treatment has added a second setting. Peritoneal dialysis and home haemodialysis bring the equipment into kitchens, bedrooms and living rooms, and the companies that make or support it often show machines beside sofas and tables rather than in clinical rooms. Symbols tend to stay simple: kidney shapes, drops, waves and circles that print clearly on a label, a machine housing or a clinic sign.

The trade meets at a few large congresses. The American Society of Nephrology’s Kidney Week, held in Denver in 2026, drew nearly 12,000 participants from close to 100 countries, the society says, and makers such as Fresenius Medical Care list it among their events. In Europe, the European Renal Association holds an annual congress, scheduled for Rotterdam in 2027 and Berlin in 2028, according to the association.

This guide sets out what can be checked about each company: who founded it, who owns it, where it works and what it makes. Where a fact rests only on a company’s own word, we say so, and the colours and typefaces shown are our own interpretation rather than any official brand standard.

Swedish-born, owned from Abu Dhabi.

Bridgepoint held Diaverum for about sixteen years. In April 2023 it agreed to sell the whole company to M42, an Abu Dhabi health group created as a joint venture of G42 Healthcare and Mubadala Health. The law firm White & Case, which advised Bridgepoint, announced the sale on 19 April 2023, and in a 2025 release Bridgepoint listed Diaverum among the companies it had sold, giving the year as 2023. The Gulf Daily News reported that the purchase made M42 the largest healthcare company in the Middle East.

Since then Diaverum has presented itself as both Swedish and part of a Gulf group. Its press releases call it “a Swedish-born, multinational healthcare organisation” and “part of the M42 group of companies.” In May 2025 it named Rafael Romanini group chief executive, succeeding Dimitris Moulavasilis, who had led the company at the time of the M42 sale; a September 2026 release gives Romanini’s titles as Diaverum CEO and M42’s chief operating officer for Europe and Latin America. That same month the company launched RenalLab, a clinical-leadership programme run by its training arm, D-Academy.

For a design guide, Diaverum shows how a clinic network can carry one name across very different health systems, from contracts in the north of England to state-funded dialysis in Central Asia, while its owner changes from a London private-equity firm to an Abu Dhabi health group. Compare Fresenius Medical Care and DaVita, the two clinic operators ranked ahead of it by English Wikipedia. For this guide we use a deep teal, a pale sky blue and a warm coral with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Diaverum’s identity on hand — save it to a board in the Made Good inspiration library.